Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results driving optimism for continued growth. Gilead Sciences' key growth drivers include robust sales from Livdelzi and ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead Sciences for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last year, ...

– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. – The funding focuses on reducing barriers to fresh food in vulnerable communities ...

Editor's note: The Fierce team will be out of office next Friday for the Thanksgiving holiday. The next edition of Chutes & Ladders will publish Dec. 5. Welcome to this week's Chutes & Ladders, our ...

Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch ...

Deborah Telman, Gilead Sciences Inc.'s top lawyer for the past three years, is relinquishing her duties as general counsel and head of corporate affairs effective Dec. 5. No reason was given Wednesday ...

Winter is tough on the lips. The blast of the heater, the colds and congestion that force occasional mouth-breathing (gross), and the wind that strips any semblance of naturally occurring moisture ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Deborah Telman is exiting months after the company paid $202 million to settle allegations that it provided illegal kickbacks to health care providers to juice sales of its HIV drugs. Deborah Telman ...